TipRanks
Grace Therapeutics (GRCE)
NASDAQ:GRCE
US Market
Want to see GRCE full AI Analyst Report?

Grace Therapeutics (GRCE) Drug Pipeline

1,208 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
GTx-104, Nimotop 30 Mg Oral Capsule
Aneurysmal Subarachnoid Hemorrhage (Asah)
Phase III
Active Not Recruiting
Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH
Jul 31, 2023
―
GTx-104, Nimodipine Capsules
Aneurysmal Subarachnoid Hemorrhage
Phase I
Completed
Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects
Jun 10, 2022
―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Grace Therapeutics (GRCE) have in its pipeline
      GRCE is currently developing the following drugs: GTx-104, Nimotop 30 Mg Oral Capsule, GTx-104, Nimodipine Capsules. These drug candidates are in various stages of clinical development as the company works toward FDA approval.